Paul Thevenot

8PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Metabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Baseline Tumor-Specific Prognosis in Early-Stage Hepatocellular Carcinoma: Time-Dependent Role of Biomarker Profile and Modified ALBI Grade.

|Apr 20, 2026
Radioembolization (90Y) achieves higher response rates and reduces progression risk compared with DEB-TACE in hepatocellular carcinoma.

|Jan 28, 2026
Virion-Independent Extracellular Vesicle (EV)-Dependent Transmission of SARS-CoV-2 as a Potential New Mechanism of Viral RNA Spread in Human Cells.

Nergiz Ekmen, Ali Riza Koksal, Dong Lin

|Sep 13, 2025
Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes.

Kelley G Núñez, Tyler Sandow, Alexandre Grahovac

|Sep 27, 2024
Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis.

Sandeep Das, Alexandra C Finney, Sumit Kumar Anand

|Jul 29, 2024
Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.

Kelley Núñez, Tyler Sandow, Juan Gimenez

Pageof 2

Frequent Collaborators

5 joint publications

Ari J Cohen

4 joint publications

Kelley Nunez

4 joint publications

Juan Gimenez

2 joint publications

Tyler Sandow